KR20030036140A - 시클로프로필-접합 피롤리딘에 기초한 디펩티딜 펩티다제ⅳ의 억제제, 그의 제조방법 및 그의 용도 - Google Patents
시클로프로필-접합 피롤리딘에 기초한 디펩티딜 펩티다제ⅳ의 억제제, 그의 제조방법 및 그의 용도 Download PDFInfo
- Publication number
- KR20030036140A KR20030036140A KR1020027011806A KR20027011806A KR20030036140A KR 20030036140 A KR20030036140 A KR 20030036140A KR 1020027011806 A KR1020027011806 A KR 1020027011806A KR 20027011806 A KR20027011806 A KR 20027011806A KR 20030036140 A KR20030036140 A KR 20030036140A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- mmol
- inhibitor
- agent
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
- C07C2603/74—Adamantanes
Abstract
Description
실시예 # | 시클로알칸 | 질량 스펙트럼M+H |
85 | 시클로펜틸 | 234 |
86 | 시클로헥실 | 248 |
87 | 시클로부틸 | 220 |
Claims (24)
- 하기 구조를 갖고 그의 모든 입체이성질체를 포함하는 화합물 및 그의 약제학적으로 허용가능한 염, 또는 그의 프로드럭 에스테르 및 그의 모든 입체이성질체.여기서, x는 0 또는 1이고 y는 0 또는 1이고 (단, y=0이면 x=1이고, y=1이면 x=0임);n은 0 또는 1이고;X는 H 또는 CN이고;R1, R2, R3및 R4는 서로 같거나 다르고 수소, 알킬, 알케닐, 알키닐, 시클로알킬, 시클로알킬알킬, 바이시클로알킬, 트리시클로알킬, 알킬시클로알킬, 히드록시알킬, 히드록시알킬시클로알킬, 히드록시시클로알킬, 히드록시바이시클로알킬, 히드록시트리시클로알킬, 바이시클로알킬알킬, 알킬티오알킬, 아릴알킬티오알킬, 시클로알케닐, 아릴, 아랄킬, 헤테로아릴, 헤테로아릴알킬, 시클로헤테로알킬 또는 시클로헤테로알킬알킬로부터 독립적으로 선택되고; 이들 모두는 가능한 탄소 원자에 수소, 할로, 알킬, 폴리할로알킬, 알콕시, 할로알콕시, 폴리할로알콕시, 알콕시카르보닐, 알케닐, 알키닐, 시클로알킬, 시클로알킬알킬, 폴리시클로알킬, 헤테로아릴아미노, 아릴아미노, 시클로헤테로알킬, 시클로헤테로알킬알킬, 히드록시, 히드록시알킬, 니트로, 시아노, 아미노, 치환된 아미노, 알킬아미노, 디알킬아미노, 티올, 알킬티오, 알킬카르보닐, 아실, 알콕시카르보닐, 아미노카르보닐, 알키닐아미노카르보닐, 알킬아미노카르보닐, 알케닐아미노카르보닐, 알킬카르보닐옥시, 알킬카르보닐아미노, 아릴카르보닐아미노, 알킬설포닐아미노, 알킬아미노카르보닐아미노, 알콕시카르보닐아미노, 알킬설포닐, 아미노설피닐, 아미노설포닐, 알킬설피닐, 설폰아미도 또는 설포닐로부터 선택되는 1, 2, 3, 4 또는 5 개의 기로 선택적으로 치환되고;R1및 R3은 선택적으로 함께 -(CR5R6)m-를 형성할 수 있고 (여기서 m은 2 내지 6이고, R5및 R6은 서로 같거나 다르고, 히드록시, 알콕시, H, 알킬, 알케닐, 알키닐, 시클로알킬, 할로, 아미노, 치환된 아미노, 시클로알킬알킬, 시클로알케닐, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, 시클로헤테로알킬, 시클로헤테로알킬알킬, 알킬카르보닐아미노, 아릴카르보닐아미노, 알콕시카르보닐아미노, 아릴옥시카르보닐아미노, 알콕시카르보닐, 아릴옥시카르보닐, 또는 알킬아미노카르보닐아미노로부터 독립적으로 선택됨), 또는 R1및 R4는 선택적으로 함께 -(CR7R8)p-를 형성하고 (여기서 p는 2 내지 6이고, R7및 R8은 서로 같거나 다르고 히드록시, 알콕시, 시아노, H, 알킬, 알케닐, 알키닐, 시클로알킬, 시클로알킬알킬, 시클로알케닐, 할로, 아미노, 치환된 아미노, 아릴, 아릴알킬, 헤테로아릴, 헤테로아릴알킬, 시클로헤테로알킬, 시클로헤테로알킬알킬, 알킬카르보닐아미노, 아릴카르보닐아미노, 알콕시카르보닐아미노, 아릴옥시카르보닐아미노, 알콕시카르보닐, 아릴옥시카르보닐, 또는 알킬아미노카르보닐아미노로부터 독립적으로 선택됨), 또는 선택적으로 R1및 R3은와 함께 N, O, S, SO 또는 SO2로부터 선택되는 총 2 내지 4개의 이종원자를 포함하는 5 내지 7원환을 형성하거나;또는 선택적으로 R1및 R3은와 함께 4 내지 8원의 시클로헤테로알킬 고리를 형성하고, 여기서 시클로헤테로알킬 고리는 그에 접합된 선택적 아릴 고리를 갖거나 그에 접합된 선택적 3 내지 7원의 시클로알킬 고리를 갖는다.
- 제1항에 있어서, 하기 구조를 갖는 화합물.
- 제1항에 있어서, 하기 구조를 갖는 화합물
- 제1항에 있어서, 하기 구조를 갖는 화합물.
- 제1항에 있어서, 하기 구조를 갖는 화합물.
- 제1항에 있어서, R3가 H이고, R1이 H, 알킬, 시클로알킬, 바이시클로알킬, 트리시클로알킬, 알킬시클로알킬, 히드록시알킬, 히드록시알킬시클로알킬, 히드록시시클로알킬, 히드록시바이시클로알킬 또는 히드록시트리시클로알킬이고, R2가 H 또는 알킬이고, n이 0이고, X가 CN인 화합물.
- 제1항에 있어서, 피롤리딘에 접합된 시클로프로필이 하기 배위를 갖는 화합물.
- 제1항에 있어서, 하기 구조를 갖는 화합물 또는 이들의 약제학적으로 허용가능한 염.
- 제8항에 있어서, 약제학적으로 허용가능한 염이 염산염 또는 트리플루오로아세트산염인 화합물.
- 제1항에 있어서, 하기 A 또는 B인 화합물.(여기서 R1은 알킬, 시클로알킬, 바이시클로알킬, 트리시클로알킬, 알킬시클로알킬, 히드록시알킬, 히드록시시클로알킬, 히드록시알킬시클로알킬, 히드록시바이시클로알킬 또는 히드록시트리시클로알킬임)(여기서 R1은 알킬, 시클로알킬, 바이시클로알킬, 트리시클로알킬, 알킬시클로알킬, 히드록시알킬, 히드록시시클로알킬, 히드록시알킬시클로알킬, 히드록시바이시클로알킬 또는 히드록시트리시클로알킬임)
- 제1항에 정의된 화합물 및 그에 대한 약제학적으로 허용가능한 담체를 포함하는 제약 조성물.
- 제1항에 정의된 DP4 억제제 화합물과 당뇨병 및 관련 질환을 치료하기 위한DP4 억제제 이외의 당뇨병 치료제, 항-비만제 및(또는) 지질-조절제를 포함하는 복합 약제.
- 제12항에 있어서, 상기 DP4 억제제 화합물 및 당뇨병 치료제를 포함하는 복합 약제.
- 제13항에 있어서, 당뇨병 치료제가 1, 2, 3 또는 그 이상의 바이구아니드, 설포닐유레아, 글루코시다제 억제제, PPAR γ 효능제, PPAR α/γ 이중 효능제, SGLT2 억제제, aP2 억제제, 글리코겐 포스포릴라제 억제제, AGE 억제제, 인슐린 민감화제, 글루카곤-유사 펩티드-1 (GLP-1) 또는 이들의 유사약, 인슐린 및(또는) 메글리티니드인 복합 약제.
- 제14항에 있어서, 당뇨병 치료제가 1, 2, 3 또는 그 이상의 메트폴민, 글리뷰리드, 글리메피리드, 글리피리드, 글리피지드, 클로르프로파미드, 글리클라지드, 아카보스, 미글리톨, 피오글리타존, 트로글리타존, 로시글리타존, 인슐린, G1-262570, 이사글리타존, JTT-501, NN-2344, L895645, YM-440, R-119702, AJ9677, 레파글리니드, 나테글리니드, KAD1129, AR-HO39242, GW-409544, KRP297, AC2993, 엑센딘-4, LY307161, NN2211 및(또는) LY315902인 복합 약제.
- 제13항에 있어서, 상기 화합물이 당뇨병 치료제에 대한 중량비가 약 0.01 내지 약 100:1인 범위 내로 존재하는 복합 약제.
- 제12항에 있어서, 항-비만제가 베타 3 아드레날린성 효능제, 리파제 억제제, 세로토닌 (및 도파민) 재흡수 억제제, 갑상선 수용체 베타 화합물, 식욕 억제제, 및(또는) 지방산 산화 상향조절제인 복합 약제.
- 제17항에 있어서, 항-비만제가 오를리스타트, ATL-962, AJ9677, L750355, CP331648, 시부트라민, 토피라메이트, 악소킨, 덱스암페타민, 펜터민, 페닐프로판올아민, 파목신 및(또는) 마진돌인 복합 약제.
- 제12항에 있어서, 지질 조절제가 MTP 억제제, HMG CoA 환원효소 억제제, 스쿠알렌 합성효소 억제제, 피브르산 유도체, LDL 수용체 활성의 상향조절제, 리폭시게나제 억제제, ACAT 억제제, 콜레스테릴 에스테르 운반 단백질 억제제, 또는 ATP 시트레이트 분해효소 억제제인 복합 약제.
- 제19항에 있어서, 지질 조절제가 프라바스타틴, 로바스타틴, 심바스타틴, 아토르바스타틴, 세리바스타틴, 플루바스타틴, 니스바스타틴, 비사스타틴, 페노피브레이트, 겜피브로질, 클로피브레이트, 임플리타피드, CP-529,414, 아바시미브, TS-962, MD-700 및(또는) LY295427인 복합 약제.
- 제19항에 있어서, DP4억제제가 지질-조절제에 대한 중량비가 약 0.01 내지 약 100:1인 범위 내로 존재하는 복합 약제.
- 제1항에 정의된 DP4 억제 화합물 및 불임 치료제, 다낭성 난소 증후군 치료제, 성장 장애 및(또는) 취약증 치료제, 항-관절염 제제, 이식시의 동종이식 거부반응 방지제, 자가면역 질환 치료제, 항-AIDS 제제, 염증성 장 질환/증후군 치료제, 신경성 식욕부진 치료제, 항-골다공증 제제 및(또는) 항-비만제를 포함하는 복합 약제.
- 치료를 필요로 하는 포유류에게 치료적 유효량의 제1항에 정의된 화합물을 투여하는 것을 포함하는, 당뇨병, 인슐린 내성, 고혈당증, 고인슐린혈증, 또는 증가된 혈중 유리 지방산 농도, 비만, X 증후군, 이상대사 증후군, 당뇨병 합병증, 고트리글리세리드혈증, 고인슐린혈증, 동맥경화증, 손상된 당 항상성, 손상된 당 내성, 불임, 다낭성 난소 증후군, 성장 장애, 취약증, 관절염, 이식시의 동종이식 거부반응, 자가면역 질환, AIDS, 장 질환, 염증성 장 증후군, 신경성 식욕부진, 골다공증, 또는 면역조절 질환 또는 만성 염증성 장 질환을 치료하는 방법.
- 제23항에 있어서, 제II형 당뇨병 및(또는) 비만을 치료하는 방법.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18855500P | 2000-03-10 | 2000-03-10 | |
US60/188,555 | 2000-03-10 | ||
PCT/US2001/007151 WO2001068603A2 (en) | 2000-03-10 | 2001-03-05 | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl iv, processes for their preparation, and their use |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020067004515A Division KR100758407B1 (ko) | 2000-03-10 | 2001-03-05 | 시클로프로필-접합 피롤리딘에 기초한 디펩티딜 펩티다제ⅳ의 억제제, 그의 제조방법 및 그의 용도 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20030036140A true KR20030036140A (ko) | 2003-05-09 |
KR100754089B1 KR100754089B1 (ko) | 2007-08-31 |
Family
ID=22693638
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020027011806A KR100754089B1 (ko) | 2000-03-10 | 2001-03-05 | 시클로프로필-접합 피롤리딘에 기초한 디펩티딜 펩티다제ⅳ의 억제제, 그의 제조방법 및 그의 용도 |
KR1020067004515A KR100758407B1 (ko) | 2000-03-10 | 2001-03-05 | 시클로프로필-접합 피롤리딘에 기초한 디펩티딜 펩티다제ⅳ의 억제제, 그의 제조방법 및 그의 용도 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020067004515A KR100758407B1 (ko) | 2000-03-10 | 2001-03-05 | 시클로프로필-접합 피롤리딘에 기초한 디펩티딜 펩티다제ⅳ의 억제제, 그의 제조방법 및 그의 용도 |
Country Status (37)
Country | Link |
---|---|
US (2) | US6395767B2 (ko) |
EP (4) | EP2272825B1 (ko) |
JP (5) | JP4460205B2 (ko) |
KR (2) | KR100754089B1 (ko) |
CN (2) | CN1698601A (ko) |
AR (1) | AR027634A1 (ko) |
AT (1) | ATE396176T1 (ko) |
AU (2) | AU4546601A (ko) |
BE (2) | BE2010C008I2 (ko) |
BR (1) | BRPI0109115B8 (ko) |
CA (1) | CA2402894C (ko) |
CO (1) | CO5280198A1 (ko) |
CY (3) | CY1108273T1 (ko) |
CZ (3) | CZ307821B6 (ko) |
DE (3) | DE60134122D1 (ko) |
DK (1) | DK1261586T3 (ko) |
EG (1) | EG25854A (ko) |
ES (4) | ES2305062T3 (ko) |
FR (1) | FR10C0010I2 (ko) |
HK (2) | HK1049330B (ko) |
HU (5) | HU230347B1 (ko) |
IL (4) | IL151372A0 (ko) |
LU (2) | LU91650I2 (ko) |
MX (1) | MXPA02008837A (ko) |
MY (1) | MY124512A (ko) |
NL (1) | NL300436I1 (ko) |
NO (3) | NO324227B1 (ko) |
NZ (1) | NZ520821A (ko) |
PE (1) | PE20020771A1 (ko) |
PL (1) | PL207041B1 (ko) |
PT (1) | PT1261586E (ko) |
RU (1) | RU2286986C2 (ko) |
SG (1) | SG152030A1 (ko) |
TW (2) | TWI258468B (ko) |
UY (2) | UY26613A1 (ko) |
WO (1) | WO2001068603A2 (ko) |
ZA (1) | ZA200206816B (ko) |
Families Citing this family (310)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0487425A (ja) * | 1990-07-31 | 1992-03-19 | Fujitsu Ltd | 回線切り替え装置 |
US6414002B1 (en) * | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
US6395767B2 (en) * | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
US7622503B2 (en) | 2000-08-24 | 2009-11-24 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and methods of use thereof |
US6573287B2 (en) * | 2001-04-12 | 2003-06-03 | Bristo-Myers Squibb Company | 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method |
WO2003002553A2 (en) * | 2001-06-27 | 2003-01-09 | Smithkline Beecham Corporation | Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
CN1990469A (zh) * | 2001-06-27 | 2007-07-04 | 史密丝克莱恩比彻姆公司 | 作为二肽酶抑制剂的氟代吡咯烷 |
DE60223920T2 (de) * | 2001-06-27 | 2008-11-13 | Smithkline Beecham Corp. | Pyrrolidine als dipeptidyl-peptidase-inhibitoren |
WO2003043624A1 (en) * | 2001-11-16 | 2003-05-30 | Bristol-Myers Squibb Company | Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein |
US20070066568A1 (en) | 2005-08-31 | 2007-03-22 | Dalton James T | Treating renal disease, burns, wounds and spinal cord injury with selective androgen receptor modulators |
US8853266B2 (en) | 2001-12-06 | 2014-10-07 | University Of Tennessee Research Foundation | Selective androgen receptor modulators for treating diabetes |
US7772433B2 (en) | 2002-02-28 | 2010-08-10 | University Of Tennessee Research Foundation | SARMS and method of use thereof |
GB0205170D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205175D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205165D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205166D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205176D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205162D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
WO2003097038A1 (en) * | 2002-05-14 | 2003-11-27 | Ralph Ryback | Method for treating dermatoses and tissue damage |
US7405234B2 (en) * | 2002-05-17 | 2008-07-29 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
US7378385B2 (en) * | 2002-08-08 | 2008-05-27 | University Of Cincinnati | Role for GLP-1 to mediate responses to disparate stressors |
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US7262207B2 (en) * | 2002-09-19 | 2007-08-28 | Abbott Laboratories | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
US7238724B2 (en) * | 2002-09-19 | 2007-07-03 | Abbott Laboratories | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
US20040121964A1 (en) * | 2002-09-19 | 2004-06-24 | Madar David J. | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
EP1567487A4 (en) * | 2002-11-15 | 2005-11-16 | Bristol Myers Squibb Co | OPEN-CHAINED, PROLYL-FROSTED MODULATORS OF ANDROGEN RECEPTOR FUNCTION |
US8309603B2 (en) | 2004-06-07 | 2012-11-13 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
US7420079B2 (en) * | 2002-12-09 | 2008-09-02 | Bristol-Myers Squibb Company | Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof |
CA2508947A1 (en) * | 2002-12-20 | 2004-07-15 | Merck & Co., Inc. | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
JP4887139B2 (ja) * | 2003-03-25 | 2012-02-29 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼインヒビター |
US7371871B2 (en) | 2003-05-05 | 2008-05-13 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
CA2524009C (en) | 2003-05-05 | 2014-04-29 | Probiodrug Ag | Use of effectors of glutaminyl and glutamate cyclases |
US7381537B2 (en) | 2003-05-05 | 2008-06-03 | Probiodrug Ag | Use of inhibitors of glutaminyl cyclases for treatment and prevention of disease |
EP1625122A1 (en) | 2003-05-14 | 2006-02-15 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
US7459474B2 (en) | 2003-06-11 | 2008-12-02 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor and method |
US6995183B2 (en) | 2003-08-01 | 2006-02-07 | Bristol Myers Squibb Company | Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods |
US7678909B1 (en) | 2003-08-13 | 2010-03-16 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
ZA200602051B (en) * | 2003-08-13 | 2007-10-31 | Takeda Pharmaceutical | 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors |
US7205409B2 (en) * | 2003-09-04 | 2007-04-17 | Abbott Laboratories | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
US20050065144A1 (en) * | 2003-09-08 | 2005-03-24 | Syrrx, Inc. | Dipeptidyl peptidase inhibitors |
US7790734B2 (en) * | 2003-09-08 | 2010-09-07 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7371759B2 (en) * | 2003-09-25 | 2008-05-13 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
JP5707014B2 (ja) | 2003-10-15 | 2015-04-22 | プロビオドルグ エージー | グルタミニル、及びグルタミン酸シクラーゼのエフェクターの使用 |
WO2005049027A2 (en) | 2003-11-03 | 2005-06-02 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
EP1689757B1 (en) * | 2003-11-12 | 2014-08-27 | Phenomix Corporation | Heterocyclic boronic acid compounds |
US7576121B2 (en) * | 2003-11-12 | 2009-08-18 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
US7767828B2 (en) * | 2003-11-12 | 2010-08-03 | Phenomix Corporation | Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
US7317109B2 (en) * | 2003-11-12 | 2008-01-08 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
US20070149451A1 (en) * | 2003-11-17 | 2007-06-28 | Holmes David G | Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent |
KR20140089408A (ko) | 2003-11-17 | 2014-07-14 | 노파르티스 아게 | 디펩티딜 펩티다제 ⅳ 억제제의 용도 |
US7420059B2 (en) * | 2003-11-20 | 2008-09-02 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
DK3366283T3 (da) | 2004-01-20 | 2021-11-22 | Novartis Ag | Direkte sammenpresningsformulering og fremgangsmåde |
US7470810B2 (en) | 2004-01-21 | 2008-12-30 | Bristol-Myers Squibb Company | Alkyl and aryl-thiotrifluoroacetates and process |
WO2005073186A1 (ja) * | 2004-01-29 | 2005-08-11 | Ono Pharmaceutical Co., Ltd. | ピロリジン誘導体 |
CN1918131B (zh) | 2004-02-05 | 2011-05-04 | 前体生物药物股份公司 | 谷氨酰胺酰基环化酶抑制剂 |
SI1712547T1 (sl) * | 2004-02-05 | 2012-04-30 | Kyorin Seiyaku Kk | Bicikloestrski derivat |
US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
CN1922139B (zh) * | 2004-02-18 | 2010-12-29 | 杏林制药株式会社 | 双环酰胺衍生物 |
US7514571B2 (en) * | 2004-02-27 | 2009-04-07 | Kyorin Pharmaceutical Co., Ltd. | Bicyclo derivative |
US20070238753A1 (en) * | 2004-02-27 | 2007-10-11 | Madar David J | Pharmaceutical Compositions as Inhibitors of Dipeptidyl Peptidase-IV (DPP-IV) |
US7732446B1 (en) | 2004-03-11 | 2010-06-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
GEP20094679B (en) * | 2004-03-15 | 2009-05-10 | Takeda Pharmaceuticals Co | Dipeptidyl peptidase inhibitors |
TW200534879A (en) * | 2004-03-25 | 2005-11-01 | Bristol Myers Squibb Co | Coated tablet formulation and method |
TW200538122A (en) * | 2004-03-31 | 2005-12-01 | Bristol Myers Squibb Co | Process for preparing a dipeptidyl peptidase Ⅳ inhibitor and intermediates employed therein |
US7741082B2 (en) | 2004-04-14 | 2010-06-22 | Bristol-Myers Squibb Company | Process for preparing dipeptidyl peptidase IV inhibitors and intermediates therefor |
US20050256314A1 (en) * | 2004-05-04 | 2005-11-17 | Soojin Kim | Process employing controlled crystallization in forming crystals of a pharmaceutical |
US7829720B2 (en) | 2004-05-04 | 2010-11-09 | Bristol-Myers Squibb Company | Process for preparing atazanavir bisulfate and novel forms |
TW200536827A (en) * | 2004-05-04 | 2005-11-16 | Bristol Myers Squibb Co | Enzymatic ammonolysis process for the preparation of intermediates for DPP IV inhibitors |
US7214702B2 (en) * | 2004-05-25 | 2007-05-08 | Bristol-Myers Squibb Company | Process for producing a dipeptidyl peptidase IV inhibitor |
TWI415635B (zh) * | 2004-05-28 | 2013-11-21 | 必治妥施貴寶公司 | 加衣錠片調製物及製備彼之方法 |
JP2008501714A (ja) * | 2004-06-04 | 2008-01-24 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼインヒビター |
US9889110B2 (en) | 2004-06-07 | 2018-02-13 | University Of Tennessee Research Foundation | Selective androgen receptor modulator for treating hormone-related conditions |
US9884038B2 (en) | 2004-06-07 | 2018-02-06 | University Of Tennessee Research Foundation | Selective androgen receptor modulator and methods of use thereof |
US7572805B2 (en) | 2004-07-14 | 2009-08-11 | Bristol-Myers Squibb Company | Pyrrolo(oxo)isoquinolines as 5HT ligands |
WO2006019965A2 (en) | 2004-07-16 | 2006-02-23 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
US7842707B2 (en) * | 2004-07-23 | 2010-11-30 | Nuada, Llc | Peptidase inhibitors |
TW200608967A (en) | 2004-07-29 | 2006-03-16 | Sankyo Co | Pharmaceutical compositions containing with diabetic agent |
US20060035954A1 (en) * | 2004-08-11 | 2006-02-16 | Sharma Padam N | Ammonolysis process for the preparation of intermediates for DPP IV inhibitors |
AR051446A1 (es) * | 2004-09-23 | 2007-01-17 | Bristol Myers Squibb Co | Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2) |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
EP1828192B1 (en) | 2004-12-21 | 2014-12-03 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7589088B2 (en) * | 2004-12-29 | 2009-09-15 | Bristol-Myers Squibb Company | Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods |
US7635699B2 (en) * | 2004-12-29 | 2009-12-22 | Bristol-Myers Squibb Company | Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods |
DOP2006000008A (es) | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
JP2008024592A (ja) * | 2005-01-28 | 2008-02-07 | Taisho Pharmaceut Co Ltd | シアノピロリジン誘導体含有固形製剤用組成物、それを含有する固形製剤及びその製造方法 |
DE602006004964D1 (de) * | 2005-02-10 | 2009-03-12 | Bristol Myers Squibb Co | Dihydrochinazolinone als 5ht-modulatoren |
JP2008115080A (ja) * | 2005-04-22 | 2008-05-22 | Taisho Pharmaceutical Co Ltd | 併用医薬 |
US7521557B2 (en) | 2005-05-20 | 2009-04-21 | Bristol-Myers Squibb Company | Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods |
US20060264433A1 (en) * | 2005-05-23 | 2006-11-23 | Backes Bradley J | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
US7825139B2 (en) * | 2005-05-25 | 2010-11-02 | Forest Laboratories Holdings Limited (BM) | Compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
MY152185A (en) | 2005-06-10 | 2014-08-29 | Novartis Ag | Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation |
US20070027178A1 (en) * | 2005-07-28 | 2007-02-01 | Bristol-Myers Squibb Company | Substituted tetrahydro-1H-pyrido[4,3-b]indoles as serotonin receptors agonists and antagonists |
DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
TW200738245A (en) * | 2005-08-22 | 2007-10-16 | Sankyo Co | Pharmaceutical composition containing FBPase inhibitor |
US7795436B2 (en) * | 2005-08-24 | 2010-09-14 | Bristol-Myers Squibb Company | Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists |
RS52110B2 (sr) | 2005-09-14 | 2018-05-31 | Takeda Pharmaceuticals Co | Inhibitori dipeptidil peptidaze za lečenje dijabetesa |
WO2007033265A1 (en) * | 2005-09-14 | 2007-03-22 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors for treating diabetis |
US20070060528A1 (en) * | 2005-09-14 | 2007-03-15 | Christopher Ronald J | Administration of dipeptidyl peptidase inhibitors |
TW200745080A (en) * | 2005-09-16 | 2007-12-16 | Takeda Pharmaceuticals Co | Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor |
JP5122462B2 (ja) * | 2005-09-16 | 2013-01-16 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼ阻害剤 |
TW200745079A (en) * | 2005-09-16 | 2007-12-16 | Takeda Pharmaceuticals Co | Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor |
TW200738266A (en) * | 2005-09-29 | 2007-10-16 | Sankyo Co | Pharmaceutical agent containing insulin resistance improving agent |
WO2007053819A2 (en) | 2005-10-31 | 2007-05-10 | Bristol-Myers Squibb Company | Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase iv and methods |
WO2007054577A1 (en) * | 2005-11-14 | 2007-05-18 | Probiodrug Ag | Cyclopropyl-fused pyrrolidine derivatives as dipeptidyl peptidase iv inhibitors |
GB0526291D0 (en) * | 2005-12-23 | 2006-02-01 | Prosidion Ltd | Therapeutic method |
CA2645154C (en) * | 2006-03-08 | 2011-11-29 | Kyorin Pharmaceutical Co., Ltd. | Method for producing aminoacetylpyrrolidinecarbonitrile derivative and production intermediate thereof |
RU2465264C2 (ru) * | 2006-03-16 | 2012-10-27 | Вертекс Фармасьютикалз Инкорпорейтед | Дейтерированные ингибиторы протеазы гепатита с |
WO2007112347A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
JP2009531456A (ja) * | 2006-03-28 | 2009-09-03 | 武田薬品工業株式会社 | (r)−3−アミノピペリジン二塩酸塩の調製 |
US20070238770A1 (en) * | 2006-04-05 | 2007-10-11 | Bristol-Myers Squibb Company | Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations |
PE20071221A1 (es) * | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
JP4521838B2 (ja) * | 2006-04-11 | 2010-08-11 | アリーナ ファーマシューティカルズ, インコーポレイテッド | 個体において骨質量を増加させるために有用である化合物を同定するためにgpr119受容体を用いる方法 |
US7728146B2 (en) | 2006-04-12 | 2010-06-01 | Probiodrug Ag | Enzyme inhibitors |
EP2014648A4 (en) * | 2006-04-17 | 2010-10-13 | Sumitomo Chemical Co | METHOD FOR PRODUCING A POLYCYCLIC PROLIN DERIVATIVE OR ACID ADDITIONAL SALT THEREOF |
EA015687B1 (ru) | 2006-05-04 | 2011-10-31 | Бёрингер Ингельхайм Интернациональ Гмбх | Полиморфы |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
US7919598B2 (en) | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
AU2007272950B2 (en) | 2006-07-12 | 2012-11-01 | University Of Tennessee Research Foundation | Substituted acylanilides and methods of use thereof |
US9844528B2 (en) | 2006-08-24 | 2017-12-19 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
US9730908B2 (en) | 2006-08-24 | 2017-08-15 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
MX2009002282A (es) | 2006-09-07 | 2009-03-20 | Nycomed Gmbh | Tratamiento de combinacion para diabetes mellitius. |
US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
CL2007002634A1 (es) * | 2006-09-13 | 2008-05-16 | Smithkline Beecham Corp | Uso de una composicion que comprende al menos un polipeptido que tiene actividad de peptido-1 semejante a glucagon (glp-1) como agente hipoglucemiante de larga duracion. |
EA017799B1 (ru) * | 2006-09-13 | 2013-03-29 | Такеда Фармасьютикал Компани Лимитед | Применение 2-[6-(3-аминопиперидин-1-ил)-3-метил-2,4-диоксо-3,4-дигидро-2н-пиримидин-1-илметил]-4-фторбензонитрила |
EP2089383B1 (en) | 2006-11-09 | 2015-09-16 | Probiodrug AG | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
US8217025B2 (en) * | 2006-11-17 | 2012-07-10 | Harbor Therapeutics, Inc. | Drug screening and treatment methods |
TW200838536A (en) * | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
EP2091948B1 (en) | 2006-11-30 | 2012-04-18 | Probiodrug AG | Novel inhibitors of glutaminyl cyclase |
EA019833B1 (ru) | 2007-01-22 | 2014-06-30 | ДЖиТиЭкс, ИНК. | Вещества, связывающие ядерные рецепторы |
US9623021B2 (en) | 2007-01-22 | 2017-04-18 | Gtx, Inc. | Nuclear receptor binding agents |
US9604931B2 (en) | 2007-01-22 | 2017-03-28 | Gtx, Inc. | Nuclear receptor binding agents |
CN101230058A (zh) * | 2007-01-23 | 2008-07-30 | 上海恒瑞医药有限公司 | 双环氮杂烷类衍生物、其制备方法及其在医药上的用途 |
DE602008003522D1 (de) | 2007-02-01 | 2010-12-30 | Takeda Pharmaceutical | Feste zubereitung mit alogliptin und pioglitazon |
WO2008098256A1 (en) * | 2007-02-09 | 2008-08-14 | Bristol-Myers Squibb Company | Methods for identifying patients with an increased likelihood of responding to dpp-iv inhibitors |
US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
US20080064701A1 (en) * | 2007-04-24 | 2008-03-13 | Ramesh Sesha | Anti-diabetic combinations |
US8795627B2 (en) | 2007-03-21 | 2014-08-05 | Raptor Pharmaceuticals Inc. | Treatment of liver disorders by administration of RAP conjugates |
PE20090185A1 (es) | 2007-03-22 | 2009-02-28 | Bristol Myers Squibb Co | Formulaciones farmaceuticas que contienen un inhibidor sglt2 |
ATE550319T1 (de) * | 2007-03-22 | 2012-04-15 | Kyorin Seiyaku Kk | Verfahren zur herstellung eines aminoacetylpyrrolidincarbonitrilderivats |
KR101361427B1 (ko) | 2007-04-03 | 2014-02-10 | 미쓰비시 타나베 파마 코퍼레이션 | 디펩티딜 펩티다아제 4 저해 화합물과 감미료와의 병용 |
ES2533484T3 (es) | 2007-04-18 | 2015-04-10 | Probiodrug Ag | Derivados de tiourea como inhibidores de la glutaminil ciclasa |
PE20090696A1 (es) * | 2007-04-20 | 2009-06-20 | Bristol Myers Squibb Co | Formas cristalinas de saxagliptina y procesos para preparar las mismas |
JP2010528023A (ja) * | 2007-05-18 | 2010-08-19 | ブリストル−マイヤーズ スクイブ カンパニー | Sglt2阻害剤の結晶構造およびその製造方法 |
CN101318925A (zh) * | 2007-06-04 | 2008-12-10 | 上海恒瑞医药有限公司 | 吡咯烷并四元环类衍生物、其制备方法及其在医药上的用途 |
EA021544B1 (ru) | 2007-06-04 | 2015-07-30 | Бен-Гурион Юниверсити Оф Дзе Негев Рисерч Энд Дивелопмент Оторити | Триарильные соединения и фармацевтические композиции, их содержащие |
PT2178513E (pt) * | 2007-06-22 | 2011-05-31 | Bristol Myers Squibb Co | Composi??es em comprimido que cont?m atazanavir |
ATE499927T1 (de) * | 2007-06-22 | 2011-03-15 | Bristol Myers Squibb Co | Tablettierte atazanavirhaltige zusammensetzungen |
CN101778624A (zh) * | 2007-06-22 | 2010-07-14 | 百时美施贵宝公司 | 含有阿扎那韦的压片组合物 |
KR20100033379A (ko) * | 2007-06-22 | 2010-03-29 | 브리스톨-마이어스 스큅 컴퍼니 | 아타자나비르를 함유하는 정제 조성물 |
PE20090938A1 (es) | 2007-08-16 | 2009-08-08 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo |
US20110112069A1 (en) * | 2007-08-17 | 2011-05-12 | Boehringer Ingelheim International Gmbh | Purin derivatives for use in the treatment of fab-related diseases |
US7968603B2 (en) | 2007-09-11 | 2011-06-28 | University Of Tennessee Research Foundation | Solid forms of selective androgen receptor modulators |
US20090076118A1 (en) * | 2007-09-13 | 2009-03-19 | Protia, Llc | Deuterium-enriched saxagliptin |
US8338450B2 (en) * | 2007-09-21 | 2012-12-25 | Lupin Limited | Compounds as dipeptidyl peptidase IV (DPP IV) inhibitors |
CL2008003653A1 (es) | 2008-01-17 | 2010-03-05 | Mitsubishi Tanabe Pharma Corp | Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica. |
US8551524B2 (en) * | 2008-03-14 | 2013-10-08 | Iycus, Llc | Anti-diabetic combinations |
PE20091730A1 (es) * | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
EP2146210A1 (en) | 2008-04-07 | 2010-01-20 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY |
US20110152340A1 (en) * | 2008-05-16 | 2011-06-23 | Bristol-Myers Squibb Company | Methods for Identifying Subjects With an Increased Likelihood of Responding to DPP-IV Inhibitors |
PE20100156A1 (es) * | 2008-06-03 | 2010-02-23 | Boehringer Ingelheim Int | Tratamiento de nafld |
US8003689B2 (en) | 2008-06-20 | 2011-08-23 | Gtx, Inc. | Metabolites of selective androgen receptor modulators and methods of use thereof |
KR20200118243A (ko) | 2008-08-06 | 2020-10-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
EP2322499A4 (en) * | 2008-08-07 | 2011-12-21 | Kyorin Seiyaku Kk | PROCESS FOR PRODUCING A BICYCLOÝ2.2.2¨OCTYLAMINE DERIVATIVE |
KR20110044780A (ko) * | 2008-08-14 | 2011-04-29 | 교린 세이야꾸 가부시키 가이샤 | 안정화된 의약 조성물 |
MX2011001525A (es) | 2008-08-15 | 2011-03-29 | Boehringer Ingelheim Int | Derivados de purina para su uso en el tratamiento de enfermedades relacionadas con fab. |
MX2011002558A (es) | 2008-09-10 | 2011-04-26 | Boehringer Ingelheim Int | Terapia de combinacion para el tratamiento de diabetes y estados relacionados. |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
LT2349324T (lt) | 2008-10-17 | 2017-12-27 | Sanofi-Aventis Deutschland Gmbh | Insulino ir glp-1 agonisto derinys |
DK2344519T3 (en) | 2008-11-07 | 2017-01-23 | Massachusetts Gen Hospital | C-TERMINAL FRAGMENTS OF GLUCAGON SIMILAR PEPTID-1 (GLP-1) |
WO2010059639A2 (en) * | 2008-11-19 | 2010-05-27 | Auspex Pharmaceuticals, Inc. | Hydroxyadamantyl inhibitors of dipeptidylpeptidase iv |
US20100144140A1 (en) * | 2008-12-10 | 2010-06-10 | Novellus Systems, Inc. | Methods for depositing tungsten films having low resistivity for gapfill applications |
DE102008062136B4 (de) | 2008-12-16 | 2012-05-03 | Kamamed Ug | Pharmazeutische Zusammensetzung auf Basis von Peptid aus Kamelmilch |
CA2745037C (en) | 2008-12-23 | 2020-06-23 | Boehringer Ingelheim International Gmbh | Salt forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8(3-(r)-amino-piperidin-1-yl)-xanthine |
TW201036975A (en) | 2009-01-07 | 2010-10-16 | Boehringer Ingelheim Int | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy |
US8706650B2 (en) * | 2009-01-14 | 2014-04-22 | Integral Analytics, Inc. | Optimization of microgrid energy use and distribution |
AR075204A1 (es) | 2009-01-29 | 2011-03-16 | Boehringer Ingelheim Int | Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2 |
US20120094894A1 (en) | 2009-02-13 | 2012-04-19 | Boehringer Ingelheim International Gmbh | Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics |
CN102307577A (zh) | 2009-02-13 | 2012-01-04 | 贝林格尔.英格海姆国际有限公司 | 包含sglt2抑制剂、dpp-iv抑制剂和任选的另一种抗糖尿病药的药物组合物及其用途 |
JPWO2010110436A1 (ja) | 2009-03-27 | 2012-10-04 | 杏林製薬株式会社 | 塩基性添加剤を含有するマトリックス型徐放性製剤 |
KR20110135411A (ko) | 2009-03-27 | 2011-12-16 | 브리스톨-마이어스 스큅 컴퍼니 | Dpp-iv 억제제로 주요 유해 심장혈관 이벤트를 예방하는 방법 |
EP2417260A1 (en) * | 2009-04-08 | 2012-02-15 | Bristol-Myers Squibb Company | A genetically stable plasmid expressing pdh and fdh enzymes |
RU2539590C2 (ru) * | 2009-04-09 | 2015-01-20 | Сандоз Аг | Кристаллические формы саксаглиптина |
WO2010146597A1 (en) | 2009-06-18 | 2010-12-23 | Lupin Limited | 2-amino-2- [8-(dimethyl carbamoyl)- 8-aza- bicyclo [3.2.1] oct-3-yl]-exo- ethanoyl derivatives as potent dpp-iv inhibitors |
AR077642A1 (es) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo |
ES2548913T3 (es) | 2009-09-11 | 2015-10-21 | Probiodrug Ag | Derivados heterocíclicos como inhibidores de glutaminil ciclasa |
EP2308847B1 (en) | 2009-10-09 | 2014-04-02 | EMC microcollections GmbH | Substituted pyridines as inhibitors of dipeptidyl peptidase IV and their application for the treatment of diabetes and related diseases |
RU2583920C2 (ru) | 2009-11-13 | 2016-05-10 | Астразенека Аб | Композиция двухслойной таблетки |
TWI468171B (zh) * | 2009-11-13 | 2015-01-11 | Sanofi Aventis Deutschland | 含glp-1激動劑及甲硫胺酸之醫藥組成物 |
PL2498759T3 (pl) | 2009-11-13 | 2019-03-29 | Astrazeneca Ab | Formulacje tabletek o natychmiastowym uwalnianiu |
ES2855146T3 (es) | 2009-11-13 | 2021-09-23 | Sanofi Aventis Deutschland | Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina |
CN107115530A (zh) | 2009-11-27 | 2017-09-01 | 勃林格殷格翰国际有限公司 | 基因型糖尿病患者利用dpp‑iv抑制剂例如利拉利汀的治疗 |
TWI562775B (en) | 2010-03-02 | 2016-12-21 | Lexicon Pharmaceuticals Inc | Methods of using inhibitors of sodium-glucose cotransporters 1 and 2 |
US9181233B2 (en) | 2010-03-03 | 2015-11-10 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
EA022420B1 (ru) | 2010-03-10 | 2015-12-30 | Пробиодруг Аг | Гетероциклические ингибиторы глутаминилциклазы (qc, ec 2.3.2.5) |
EP2547339A1 (en) | 2010-03-18 | 2013-01-23 | Boehringer Ingelheim International GmbH | Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions |
EP2368874A1 (en) | 2010-03-26 | 2011-09-28 | Sandoz AG | Racemisation of (R)-N-Boc-3-hydroxyadamant-1-yl glycine |
WO2011125011A1 (en) * | 2010-04-05 | 2011-10-13 | Cadila Pharmaceuticals Limited | Novel hypoglycemic compounds |
US20130023494A1 (en) | 2010-04-06 | 2013-01-24 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
WO2011140328A1 (en) | 2010-05-05 | 2011-11-10 | Teva Pharmaceutical Industries Ltd. | Saxagliptin intermediates, saxagliptin polymorphs, and processes for preparation thereof |
AU2011249722B2 (en) | 2010-05-05 | 2015-09-17 | Boehringer Ingelheim International Gmbh | Combination therapy |
KR20220025926A (ko) | 2010-06-24 | 2022-03-03 | 베링거 인겔하임 인터내셔날 게엠베하 | 당뇨병 요법 |
WO2012017028A1 (en) | 2010-08-06 | 2012-02-09 | Sandoz Ag | A novel crystalline compound comprising saxagliptin and phosphoric acid |
WO2012017029A1 (en) | 2010-08-06 | 2012-02-09 | Sandoz Ag | Novel salts of saxagrliptin with organic di-acids |
CN103179978A (zh) | 2010-08-30 | 2013-06-26 | 赛诺菲-安万特德国有限公司 | Ave0010用于制造供治疗2型糖尿病用的药物的用途 |
EP2611770A1 (en) | 2010-09-03 | 2013-07-10 | Sandoz AG | Process for the reductive amination of -keto carboxylic acids |
US20130224296A1 (en) | 2010-09-03 | 2013-08-29 | Bristol-Myers Squibb Company | Drug Formulations Using Water Soluble Antioxidants |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
BR112013008100A2 (pt) | 2010-09-22 | 2016-08-09 | Arena Pharm Inc | "moduladores do receptor de gpr19 e o tratamento de distúrbios relacionados a eles." |
US20120077778A1 (en) | 2010-09-29 | 2012-03-29 | Andrea Bourdelais | Ladder-Frame Polyether Conjugates |
US8410288B2 (en) | 2010-10-04 | 2013-04-02 | Teva Pharmaceutical Industries Ltd. | Polymorphs of Saxagliptin hydrochloride and processes for preparing them |
US9040481B2 (en) | 2010-11-02 | 2015-05-26 | The General Hospital Corporation | Methods for treating steatotic disease |
AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
TWI631963B (zh) | 2011-01-05 | 2018-08-11 | 雷西肯製藥股份有限公司 | 包含鈉-葡萄糖共同輸送體1與2之抑制劑的組合物與應用方法 |
US10017470B2 (en) | 2011-01-31 | 2018-07-10 | Cadila Healthcare Limited | Treatment for lipodystrophy |
JP2014504639A (ja) | 2011-02-01 | 2014-02-24 | ブリストル−マイヤーズ スクイブ カンパニー | アミン化合物を含む医薬製剤 |
DK2686313T3 (en) | 2011-03-16 | 2016-05-02 | Probiodrug Ag | Benzimidazole derivatives as inhibitors of glutaminyl cyclase |
WO2012135570A1 (en) | 2011-04-01 | 2012-10-04 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
US20140066369A1 (en) | 2011-04-19 | 2014-03-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
WO2012145604A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
US20140038889A1 (en) | 2011-04-22 | 2014-02-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
EP2729157B1 (en) | 2011-07-06 | 2019-01-16 | The General Hospital Corporation | A pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1) for use in treatment |
KR101985384B1 (ko) | 2011-07-15 | 2019-06-03 | 베링거 인겔하임 인터내셔날 게엠베하 | 치환된 퀴나졸린, 이의 제조 및 약제학적 조성물에서의 이의 용도 |
JP6367115B2 (ja) | 2011-08-29 | 2018-08-01 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 2型糖尿病患者の血糖コントロールに使用する組合せ医薬 |
AR087744A1 (es) | 2011-09-01 | 2014-04-16 | Sanofi Aventis Deutschland | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa |
US20140302150A1 (en) | 2011-09-07 | 2014-10-09 | Umit Cifter | Dpp-iv inhibitor formulations |
ES2487271T3 (es) | 2011-10-06 | 2014-08-20 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Formulaciones de dosificación sólidas inhibidoras de DPP-IV |
WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
JPWO2013081100A1 (ja) * | 2011-11-30 | 2015-04-27 | 積水メディカル株式会社 | アダマンチルヒダントイン化合物 |
US9115082B2 (en) | 2012-01-18 | 2015-08-25 | Catherine Yang | Dipeptidyl-peptidase-IV inhibitors for treatment of type 2 diabetes complex with hypertension |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
US20150087686A1 (en) | 2012-04-25 | 2015-03-26 | Enantia, S.L. | Crystalline forms of saxagliptin |
EP2849755A1 (en) | 2012-05-14 | 2015-03-25 | Boehringer Ingelheim International GmbH | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
US8664443B2 (en) | 2012-05-23 | 2014-03-04 | Divi's Laboratories Ltd. | Process for the preparation of (1S, 3S, 5S)-2-[2(S)-2-amino-2-(3-hydroxy-1-adamantan-1-yl) acetyl]-2-azabicyclo [3.1.0] hexane-3-carbonitrile |
US9994523B2 (en) | 2012-05-24 | 2018-06-12 | Apotex Inc. | Salts of Saxagliptin with organic acids |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
WO2014006569A2 (en) | 2012-07-02 | 2014-01-09 | Ranbaxy Laboratories Limited | Saxagliptin salts |
CN103539724B (zh) * | 2012-07-12 | 2017-09-26 | 博瑞生物医药(苏州)股份有限公司 | 沙格列汀单一立体异构体的新晶型和纯化方法 |
US9622992B2 (en) | 2012-07-13 | 2017-04-18 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
US10987334B2 (en) | 2012-07-13 | 2021-04-27 | University Of Tennessee Research Foundation | Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs) |
US10258596B2 (en) | 2012-07-13 | 2019-04-16 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
CN104754939A (zh) | 2012-07-13 | 2015-07-01 | Gtx公司 | 用选择性雄激素受体调节剂(sarm)治疗雄激素受体(ar)阳性乳癌的方法 |
US9969683B2 (en) | 2012-07-13 | 2018-05-15 | Gtx, Inc. | Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS) |
US10314807B2 (en) | 2012-07-13 | 2019-06-11 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
US9744149B2 (en) | 2012-07-13 | 2017-08-29 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
WO2014030051A1 (en) | 2012-08-23 | 2014-02-27 | Aurobindo Pharma Limited | Stable pharmaceutical compositions comprising saxagliptin |
WO2014057495A1 (en) | 2012-10-11 | 2014-04-17 | Lee Pharma Limited | A process for industrial preparation of [(s)-n-tert butoxycarbonyl-3-hydroxy]adamantylglycine |
TWI500613B (zh) | 2012-10-17 | 2015-09-21 | Cadila Healthcare Ltd | 新穎之雜環化合物 |
WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
PL3489226T3 (pl) | 2012-11-20 | 2021-08-02 | Lexicon Pharmaceuticals, Inc. | Inhibitory kotransportera glukozowo-sodowego 1 |
WO2014096983A1 (en) | 2012-12-21 | 2014-06-26 | Wockhardt Limited | Stable pharmaceutical compositions of saxagliptin or salts thereof |
WO2014096982A1 (en) | 2012-12-21 | 2014-06-26 | Wockhardt Limited | Stable pharmaceutical compositions of saxagliptin or salts thereof |
WO2014108830A1 (en) | 2013-01-10 | 2014-07-17 | Wockhardt Limited | A process for preparing pharmaceutically acceptable salt of saxagliptin |
ITMI20130132A1 (it) | 2013-01-30 | 2014-07-31 | Laboratorio Chimico Int Spa | Procedimento per la preparazione di intermedi di sintesi di saxagliptina e nuovi composti |
TWI641381B (zh) | 2013-02-04 | 2018-11-21 | 法商賽諾菲公司 | 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物 |
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
CN104059068B (zh) * | 2013-03-20 | 2017-02-08 | 中国科学院上海药物研究所 | β‑氨基羰基类化合物、其制备方法、药物组合物及其用途 |
CN104098481B (zh) * | 2013-04-10 | 2016-05-11 | 浙江九洲药物科技有限公司 | 一种沙格列汀中间体的制备方法 |
IN2013MU01468A (ko) | 2013-04-22 | 2015-04-17 | Cadila Healthcare Ltd | |
WO2014193528A1 (en) * | 2013-04-29 | 2014-12-04 | Anovel Pharmaceuticals, Llc | Amorphous dosage forms and methods |
EP3004053B1 (en) | 2013-05-30 | 2021-03-24 | Cadila Healthcare Limited | A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities |
AU2014274812B2 (en) | 2013-06-05 | 2018-09-27 | Bausch Health Ireland Limited | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
TW201636015A (zh) | 2013-07-05 | 2016-10-16 | 卡地拉保健有限公司 | 協同性組成物 |
IN2013MU02470A (ko) | 2013-07-25 | 2015-06-26 | Cadila Healthcare Ltd | |
EP2832723B1 (en) | 2013-07-29 | 2017-02-15 | Zentiva, a.s. | Stabilised amorphous forms of Saxagliptin |
WO2015031595A1 (en) * | 2013-08-28 | 2015-03-05 | Amneal Pharmaceuticals Llc | A process for preparation of saxagliptin and its hydrochloride salt |
US10112898B2 (en) | 2013-09-06 | 2018-10-30 | Cadila Healthcare Limited | Process for the preparation of saroglitazar pharmaceutical salts |
ITMI20131677A1 (it) * | 2013-10-10 | 2015-04-11 | Olon Spa | Procedimento per la preparazione di saxagliptina |
JP6657101B2 (ja) | 2013-11-05 | 2020-03-04 | ベン グリオン ユニバーシティ オブ ザ ネガフ リサーチ アンド ディベロップメント オーソリティ | 糖尿病及びそれから生じる疾患合併症の治療のための化合物 |
WO2015067223A1 (en) | 2013-11-06 | 2015-05-14 | Zentiva, K., S. | L-tartrate salt of (1s,3s,5s)-2-[(2s)-2-amino-2-(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl) acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile and process for preparation thereof |
WO2015071887A1 (en) | 2013-11-18 | 2015-05-21 | Ranbaxy Laboratories Limited | Oral pharmaceutical compositions of saxagliptin |
WO2015071889A1 (en) | 2013-11-18 | 2015-05-21 | Ranbaxy Laboratories Limited | Oral compositions of saxagliptin |
WO2015087262A1 (en) | 2013-12-11 | 2015-06-18 | Ranbaxy Laboratories Limited | Process for the preparation of saxagliptin and its intermediates |
RU2016132340A (ru) | 2014-01-09 | 2018-02-14 | Санофи | Стабилизированные фармацевтические составы на основе инсулина аспарта |
AU2015205624A1 (en) | 2014-01-09 | 2016-07-14 | Sanofi | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
RU2016132386A (ru) | 2014-01-09 | 2018-02-14 | Санофи | Стабилизированные фармацевтические составы без глицерина на основе инсулиновых аналогов и/или инсулиновых производных |
JP6615109B2 (ja) | 2014-02-28 | 2019-12-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Dpp−4阻害薬の医学的使用 |
CZ2014177A3 (cs) * | 2014-03-24 | 2015-10-07 | Zentiva, K.S. | Způsob výroby saxagliptinu |
RU2016146826A (ru) | 2014-05-30 | 2018-07-04 | Пфайзер Инк. | Производные карбонитрилов как селективные модуляторы андрогенового рецептора |
WO2016016770A1 (en) | 2014-07-26 | 2016-02-04 | Wockhardt Limited | A novel modified release pharmaceutical composition of sitagliptin or pharmaceutically acceptable salt thereof |
GB201415598D0 (en) | 2014-09-03 | 2014-10-15 | Univ Birmingham | Elavated Itercranial Pressure Treatment |
CR20170314A (es) | 2014-12-12 | 2017-10-20 | Sanofi Aventis Deutschland | Formulación de relación fija de insulina glargina/lixisenatida |
CN104557667A (zh) * | 2014-12-12 | 2015-04-29 | 山东省药学科学院 | 2-氰基吡咯烷类化合物、制备方法及其应用 |
KR20180006881A (ko) | 2015-03-09 | 2018-01-19 | 인테크린 테라퓨틱스, 아이엔씨. | 비알코올성 지방간 질환 및/또는 지방이영양증의 치료 방법 |
TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患治療 |
TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患之治療 |
CN105037245B (zh) * | 2015-08-03 | 2017-04-12 | 沧州那瑞化学科技有限公司 | 一种沙格列汀中间体的制备方法 |
US10385017B2 (en) | 2015-10-14 | 2019-08-20 | Cadila Healthcare Limited | Pyrrole compound, compositions and process for preparation thereof |
KR101715682B1 (ko) | 2015-10-29 | 2017-03-13 | 경동제약 주식회사 | 삭사글립틴의 제조를 위한 신규 중간체, 이의 제조방법 및 이를 이용한 삭사글립틴의 제조방법 |
CA3022202A1 (en) | 2016-06-10 | 2017-12-14 | Boehringer Ingelheim International Gmbh | Combinations of linagliptin and metformin |
BR112019011740A2 (pt) | 2016-12-09 | 2019-10-29 | Cadila Healthcare Ltd | composição farmacêutica e método para o tratamento de colangite biliar primária |
WO2018162722A1 (en) | 2017-03-09 | 2018-09-13 | Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke | Dpp-4 inhibitors for use in treating bone fractures |
AU2018249822A1 (en) | 2017-04-03 | 2019-10-31 | Coherus Biosciences Inc. | PPArgamma agonist for treatment of progressive supranuclear palsy |
ES2812698T3 (es) | 2017-09-29 | 2021-03-18 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
CN109970620B (zh) * | 2017-12-27 | 2022-07-12 | 江苏威凯尔医药科技有限公司 | 一种制备沙格列汀中间体的方法 |
CA3103425A1 (en) | 2018-06-14 | 2019-12-19 | Robert Peter PRYBOLSKY | Methods for lowering blood sugar with a dipeptidyl peptidase-4 inhibitor pharmaceutical composition |
BR112021000139A2 (pt) | 2018-07-19 | 2021-04-06 | Astrazeneca Ab | Métodos de tratamento da hfpef empregando dapagliflozina e composições compreendendo a mesma |
US10968192B2 (en) | 2018-09-26 | 2021-04-06 | Lexicon Pharmaceuticals, Inc. | Crystalline solid forms of N-(1-((2-(dimethylamino)ethyl)amino)-2-methyl-1-oxopropan-2-yl)-4-(4-(2-methyl-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2H-pyran-2-yl)benzyl)phenyl)butanamide and methods of their synthesis |
RU2712097C1 (ru) * | 2018-09-28 | 2020-01-24 | Общество с ограниченной ответственностью "Необиотек" | Ингибитор дипептидилпептидазы-4 для лечения сахарного диабета 2-го типа, соединения (варианты) |
RU2727898C1 (ru) * | 2020-02-25 | 2020-07-24 | Общество с ограниченной ответственностью «Необиотек» | Фармацевтическая композиция на основе действующего вещества, ингибитора дипептидилпептидазы-4, для предупреждения развития и лечения сахарного диабета 2 типа |
US20220023252A1 (en) | 2020-07-27 | 2022-01-27 | Astrazeneca Ab | Methods of treating chronic kidney disease with dapagliflozin |
WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
CN113666846B (zh) * | 2021-08-31 | 2023-06-27 | 济南立德医药技术有限公司 | 沙格列汀中间体的合成方法 |
WO2023144722A1 (en) | 2022-01-26 | 2023-08-03 | Astrazeneca Ab | Dapagliflozin for use in the treatment of prediabetes or reducing the risk of developing type 2 diabetes |
Family Cites Families (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3325478A (en) * | 1964-11-17 | 1967-06-13 | Du Pont | alpha-amino-1-adamantylmethyl penicillins |
US3674836A (en) | 1968-05-21 | 1972-07-04 | Parke Davis & Co | 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof |
US4027009A (en) | 1973-06-11 | 1977-05-31 | Merck & Co., Inc. | Compositions and methods for depressing blood serum cholesterol |
JPS5246949B2 (ko) * | 1973-10-19 | 1977-11-29 | ||
YU36151B (en) * | 1974-05-16 | 1982-02-25 | Pliva Zagreb | Process for preparing alpha-amino-2-adamantyl acetic acid |
JPS5612114B2 (ko) | 1974-06-07 | 1981-03-18 | ||
US4183857A (en) | 1978-07-06 | 1980-01-15 | Shell Oil Company | 3-Benzyl-3-azabicyclo(3.1.0)hexane-2,4-dione |
NO154918C (no) | 1977-08-27 | 1987-01-14 | Bayer Ag | Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin. |
CA1117127A (en) | 1978-06-27 | 1982-01-26 | Janet A. Day | Derivatives of 3-azabicyclo(3.1.0)hexane and a process for their preparation |
US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
DE2951135A1 (de) | 1979-12-19 | 1981-06-25 | Hoechst Ag, 6230 Frankfurt | Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung |
MX7065E (es) | 1980-06-06 | 1987-04-10 | Sankyo Co | Un procedimiento microbiologico para preparar derivados de ml-236b |
US4450171A (en) | 1980-08-05 | 1984-05-22 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
US4448784A (en) | 1982-04-12 | 1984-05-15 | Hoechst-Roussel Pharmaceuticals, Inc. | 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof |
US5354772A (en) | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
DE3324263A1 (de) | 1983-07-06 | 1985-01-17 | Hoechst Ag, 6230 Frankfurt | Derivate der 2-azabicyclo(3.1.0)hexan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung sowie 2-azabicyclo(3.1.0)hexan-derivate als zwischenprodukte und verfahren zu deren herstellung |
JPS6051189A (ja) | 1983-08-30 | 1985-03-22 | Sankyo Co Ltd | チアゾリジン誘導体およびその製造法 |
DE3536687A1 (de) | 1985-10-15 | 1987-04-16 | Hoechst Ag | Verfahren zur behandlung von atherosklerose, thrombose und der peripheren gefaesskrankheit |
DE3543999A1 (de) | 1985-12-13 | 1987-06-19 | Bayer Ag | Hochreine acarbose |
US5614492A (en) | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
US4759923A (en) | 1987-06-25 | 1988-07-26 | Hercules Incorporated | Process for lowering serum cholesterol using poly(diallylmethylamine) derivatives |
JP2569746B2 (ja) | 1987-08-20 | 1997-01-08 | 日産化学工業株式会社 | キノリン系メバロノラクトン類 |
US4924024A (en) | 1988-01-11 | 1990-05-08 | E. R. Squibb & Sons, Inc. | Phosphorus-containing squalene synthetase inhibitors, new intermediates and method |
US4871721A (en) | 1988-01-11 | 1989-10-03 | E. R. Squibb & Sons, Inc. | Phosphorus-containing squalene synthetase inhibitors |
NO177005C (no) | 1988-01-20 | 1995-07-05 | Bayer Ag | Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen |
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
DE3926606A1 (de) | 1989-08-11 | 1991-02-14 | Hoechst Ag | Verfahren zur behandlung der cardialen sowie der vasculaeren hypertrophie und hyperplasie |
US5462928A (en) | 1990-04-14 | 1995-10-31 | New England Medical Center Hospitals, Inc. | Inhibitors of dipeptidyl-aminopeptidase type IV |
US5177080A (en) | 1990-12-14 | 1993-01-05 | Bayer Aktiengesellschaft | Substituted pyridyl-dihydroxy-heptenoic acid and its salts |
JP2648897B2 (ja) | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
JPH07504158A (ja) | 1991-10-22 | 1995-05-11 | ニュー イングランド メディカル センター ホスピタルズ インク | ジペプチジル−アミノペプチダーゼiv型のインヒビタ |
US5595872A (en) | 1992-03-06 | 1997-01-21 | Bristol-Myers Squibb Company | Nucleic acids encoding microsomal trigyceride transfer protein |
DK36392D0 (da) | 1992-03-19 | 1992-03-19 | Novo Nordisk As | Anvendelse af kemisk forbindelse |
US5447954A (en) | 1992-05-05 | 1995-09-05 | Smithkline Beecham P.L.C. | Phenylderivate as inhibitors of ATP citrate lyase |
US5712396A (en) | 1992-10-28 | 1998-01-27 | Magnin; David R. | α-phosphonosulfonate squalene synthetase inhibitors |
US5594016A (en) | 1992-12-28 | 1997-01-14 | Mitsubishi Chemical Corporation | Naphthalene derivatives |
CA2150372C (en) | 1993-01-19 | 2002-08-20 | Nancy L. Mills | Stable oral ci-981 formulation and process of preparing same |
US5346701A (en) | 1993-02-22 | 1994-09-13 | Theratech, Inc. | Transmucosal delivery of macromolecular drugs |
US5739135A (en) | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
IL111785A0 (en) | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
US5776983A (en) | 1993-12-21 | 1998-07-07 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
US5488064A (en) | 1994-05-02 | 1996-01-30 | Bristol-Myers Squibb Company | Benzo 1,3 dioxole derivatives |
US5385929A (en) | 1994-05-04 | 1995-01-31 | Warner-Lambert Company | [(Hydroxyphenylamino) carbonyl] pyrroles |
US5561146A (en) | 1994-06-10 | 1996-10-01 | Bristol-Myers Squibb Company | Modified guanidino and amidino thrombin inhibitors |
US5491134A (en) | 1994-09-16 | 1996-02-13 | Bristol-Myers Squibb Company | Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives |
US5541204A (en) | 1994-12-02 | 1996-07-30 | Bristol-Myers Squibb Company | Aryloxypropanolamine β 3 adrenergic agonists |
US5620997A (en) | 1995-05-31 | 1997-04-15 | Warner-Lambert Company | Isothiazolones |
WO1996039384A1 (en) | 1995-06-06 | 1996-12-12 | Pfizer, Inc. | Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors |
DK0832066T3 (da) | 1995-06-06 | 2001-11-19 | Pfizer | Substituerede N-(indol-2-carbonyl)amider og derivater som glycogenphosphorylaseinhibitorer |
AU6966696A (en) | 1995-10-05 | 1997-04-28 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
CZ121298A3 (cs) | 1995-10-25 | 1998-07-15 | E. I. Du Pont De Nemours And Company | Herbicidní sulfonamidy |
CA2240024A1 (en) | 1995-12-13 | 1997-06-19 | The Regents Of The University Of California | Nuclear receptor ligands and ligand binding domains |
US5770615A (en) | 1996-04-04 | 1998-06-23 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
DE19616486C5 (de) | 1996-04-25 | 2016-06-30 | Royalty Pharma Collection Trust | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
US5962440A (en) | 1996-05-09 | 1999-10-05 | Bristol-Myers Squibb Company | Cyclic phosphonate ester inhibitors of microsomal triglyceride transfer protein and method |
US5885983A (en) | 1996-05-10 | 1999-03-23 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
US5827875A (en) | 1996-05-10 | 1998-10-27 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
HRP970330B1 (en) | 1996-07-08 | 2004-06-30 | Bayer Ag | Cycloalkano pyridines |
US6011155A (en) | 1996-11-07 | 2000-01-04 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
TW492957B (en) * | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
US5952322A (en) | 1996-12-05 | 1999-09-14 | Pfizer Inc. | Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors |
US5760246A (en) | 1996-12-17 | 1998-06-02 | Biller; Scott A. | Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method |
GB9713739D0 (en) | 1997-06-27 | 1997-09-03 | Karobio Ab | Thyroid receptor ligands |
DE19742601A1 (de) * | 1997-09-26 | 1999-04-29 | Siemens Ag | Verfahren und Vorrichtung zur Erzeugung von Rahmen um Videobilder |
UA57811C2 (uk) | 1997-11-21 | 2003-07-15 | Пфайзер Продактс Інк. | Фармацевтична композиція, що містить інгібітор альдозоредуктази та інгібітор глікогенфосфорилази (варіанти), комплект, який її включає, та способи лікування ссавців зі станом інсулінорезистентності |
EP2574336A1 (en) | 1998-02-02 | 2013-04-03 | Trustees Of Tufts College | Use of dipeptidylpeptidase inhibitors to regulate glucose metabolism |
US5998463A (en) | 1998-02-27 | 1999-12-07 | Pfizer Inc | Glycogen phosphorylase inhibitors |
IL136588A0 (en) | 1998-02-27 | 2001-06-14 | Pfizer Prod Inc | N-[(substituted five-membered di-or triaza diunsaturated ring) carbonyl] guanidine derivatives for the treatment of ischemia |
PT1064298E (pt) | 1998-03-19 | 2009-01-02 | Vertex Pharma | Inibidores de caspasas |
DE19828114A1 (de) | 1998-06-24 | 2000-01-27 | Probiodrug Ges Fuer Arzneim | Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV |
EP0978279A1 (en) | 1998-08-07 | 2000-02-09 | Pfizer Products Inc. | Inhibitors of human glycogen phosphorylase |
BR9913153A (pt) | 1998-08-21 | 2001-05-15 | Point Therapeutics Inc | Normalização da atividade do substrato |
CO5150173A1 (es) | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
WO2000038722A1 (en) | 1998-12-23 | 2000-07-06 | G.D. Searle & Co. | COMBINATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG CoA REDUCTASE INHIBITORS FOR CARDIOVASCULAR INDICATIONS |
AU760174B2 (en) | 1999-02-09 | 2003-05-08 | Bristol-Myers Squibb Company | Lactam inhibitors of FXa and method |
JP2002536410A (ja) | 1999-02-12 | 2002-10-29 | ノボ ノルディスク アクティーゼルスカブ | 肥満の治療又は予防もしくは食欲の調節を目的とした薬学的組成物の製造におけるピロリジン誘導体の使用 |
WO2000053171A1 (en) | 1999-03-05 | 2000-09-14 | Molteni L. E C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. | Use of metformin in the preparation of pharmaceutical compositions capable of inhibiting the enzyme dipeptidyl peptidase iv |
GB9906714D0 (en) | 1999-03-23 | 1999-05-19 | Ferring Bv | Compositions for improving fertility |
GB9906715D0 (en) | 1999-03-23 | 1999-05-19 | Ferring Bv | Compositions for promoting growth |
ES2215570T3 (es) | 1999-04-01 | 2004-10-16 | Pfizer Products Inc. | Compuestos para tratar y prevenir complicaciones diabeticas. |
JP4121215B2 (ja) | 1999-05-17 | 2008-07-23 | 財団法人微生物化学研究会 | スルフォスチン類縁体、並びにスルフォスチン及びその類縁体の製造方法 |
US6110949A (en) | 1999-06-24 | 2000-08-29 | Novartis Ag | N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
US6395767B2 (en) * | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
EP1358178A2 (en) | 2001-01-30 | 2003-11-05 | Bristol-Myers Squibb Company | Sulfonamide lactam inhibitors of factor xa |
DE10132375A1 (de) | 2001-07-07 | 2003-01-16 | Trench Germany Gmbh | Verfahren und Vorrichtung zur Herstellung eines elektrischen Kunststoffisolators |
EP1789376A1 (en) | 2004-09-17 | 2007-05-30 | Albemarle Corporation | Synthesis process for 2-(3-hydroxy-1-adamantyl)-2-oxoacetic acid |
US7205432B2 (en) | 2005-05-31 | 2007-04-17 | Kemfine Oy | Process for the preparation of adamantane derivatives |
KR101386282B1 (ko) | 2005-06-17 | 2014-04-17 | 아포지 바이오테크놀로지 코포레이션 | 스핑고신 키나제 저해제 |
-
2001
- 2001-02-16 US US09/788,173 patent/US6395767B2/en not_active Ceased
- 2001-02-28 EG EG2001020212A patent/EG25854A/xx active
- 2001-03-05 MX MXPA02008837A patent/MXPA02008837A/es active IP Right Grant
- 2001-03-05 EP EP10178907.1A patent/EP2272825B1/en not_active Expired - Lifetime
- 2001-03-05 DE DE60134122T patent/DE60134122D1/de not_active Expired - Lifetime
- 2001-03-05 KR KR1020027011806A patent/KR100754089B1/ko active IP Right Review Request
- 2001-03-05 TW TW090104965A patent/TWI258468B/zh active
- 2001-03-05 WO PCT/US2001/007151 patent/WO2001068603A2/en active Application Filing
- 2001-03-05 CA CA2402894A patent/CA2402894C/en not_active Expired - Lifetime
- 2001-03-05 HU HU1200545A patent/HU230347B1/hu unknown
- 2001-03-05 TW TW095105942A patent/TW200624420A/zh unknown
- 2001-03-05 DE DE122010000008C patent/DE122010000008I1/de active Pending
- 2001-03-05 EP EP15186007.9A patent/EP2995615B1/en not_active Expired - Lifetime
- 2001-03-05 SG SG200405783-2A patent/SG152030A1/en unknown
- 2001-03-05 PL PL365520A patent/PL207041B1/pl unknown
- 2001-03-05 ES ES01918383T patent/ES2305062T3/es not_active Expired - Lifetime
- 2001-03-05 KR KR1020067004515A patent/KR100758407B1/ko active IP Right Grant
- 2001-03-05 CZ CZ2015493A patent/CZ307821B6/cs not_active IP Right Cessation
- 2001-03-05 CN CNA2005100785188A patent/CN1698601A/zh active Pending
- 2001-03-05 IL IL15137201A patent/IL151372A0/xx unknown
- 2001-03-05 ES ES05005368.5T patent/ES2456667T3/es not_active Expired - Lifetime
- 2001-03-05 JP JP2001567699A patent/JP4460205B2/ja not_active Expired - Lifetime
- 2001-03-05 PT PT01918383T patent/PT1261586E/pt unknown
- 2001-03-05 CZ CZ2014-33A patent/CZ307784B6/cs not_active IP Right Cessation
- 2001-03-05 HU HU0302792A patent/HU228110B1/hu active Protection Beyond IP Right Term
- 2001-03-05 RU RU2002125491/04A patent/RU2286986C2/ru active Protection Beyond IP Right Term
- 2001-03-05 AU AU4546601A patent/AU4546601A/xx active Pending
- 2001-03-05 DK DK01918383T patent/DK1261586T3/da active
- 2001-03-05 EP EP01918383A patent/EP1261586B1/en not_active Expired - Lifetime
- 2001-03-05 ES ES15186007T patent/ES2768961T3/es not_active Expired - Lifetime
- 2001-03-05 HU HU1200546A patent/HU230380B1/hu unknown
- 2001-03-05 CZ CZ2002-2974A patent/CZ304355B6/cs unknown
- 2001-03-05 NZ NZ520821A patent/NZ520821A/en not_active IP Right Cessation
- 2001-03-05 AU AU2001245466A patent/AU2001245466B2/en active Active
- 2001-03-05 CN CNB018063152A patent/CN1213028C/zh not_active Expired - Lifetime
- 2001-03-05 ES ES10178907.1T patent/ES2553573T3/es not_active Expired - Lifetime
- 2001-03-05 BR BRPI0109115A patent/BRPI0109115B8/pt not_active IP Right Cessation
- 2001-03-05 EP EP05005368.5A patent/EP1559710B1/en not_active Expired - Lifetime
- 2001-03-05 AT AT01918383T patent/ATE396176T1/de active
- 2001-03-08 CO CO01018857A patent/CO5280198A1/es active IP Right Grant
- 2001-03-09 AR ARP010101122A patent/AR027634A1/es active IP Right Grant
- 2001-03-09 MY MYPI20011103A patent/MY124512A/en unknown
- 2001-03-12 UY UY26613A patent/UY26613A1/es not_active IP Right Cessation
- 2001-06-12 PE PE2001000554A patent/PE20020771A1/es not_active Application Discontinuation
-
2002
- 2002-08-21 IL IL151372A patent/IL151372A/en active Protection Beyond IP Right Term
- 2002-08-26 ZA ZA200206816A patent/ZA200206816B/en unknown
- 2002-09-09 NO NO20024295A patent/NO324227B1/no not_active IP Right Cessation
-
2003
- 2003-02-14 HK HK03101079.9A patent/HK1049330B/zh unknown
-
2006
- 2006-07-23 IL IL177018A patent/IL177018A0/en active IP Right Grant
- 2006-07-23 IL IL177019A patent/IL177019A/en active IP Right Grant
-
2008
- 2008-08-20 CY CY20081100885T patent/CY1108273T1/el unknown
-
2010
- 2010-01-14 JP JP2010006181A patent/JP5427047B2/ja not_active Expired - Lifetime
- 2010-02-11 BE BE2010C008C patent/BE2010C008I2/fr unknown
- 2010-02-17 LU LU91650C patent/LU91650I2/fr unknown
- 2010-02-17 NL NL300436C patent/NL300436I1/nl unknown
- 2010-02-22 FR FR10C0010C patent/FR10C0010I2/fr active Active
- 2010-03-16 NO NO2010006C patent/NO2010006I2/no unknown
- 2010-03-30 CY CY2010005C patent/CY2010005I1/el unknown
-
2011
- 2011-06-24 HK HK11106580.0A patent/HK1152516A1/zh not_active IP Right Cessation
- 2011-12-01 US US13/308,658 patent/USRE44186E1/en not_active Expired - Lifetime
-
2012
- 2012-04-18 BE BE2012C016C patent/BE2012C016I2/fr unknown
- 2012-04-23 DE DE201212000023 patent/DE122012000023I1/de active Pending
- 2012-04-24 CY CY2012009C patent/CY2012009I1/el unknown
- 2012-04-25 LU LU91985C patent/LU91985I2/fr unknown
- 2012-05-21 NO NO2012009C patent/NO2012009I2/no unknown
- 2012-11-30 JP JP2012263345A patent/JP2013040219A/ja active Pending
- 2012-12-14 HU HUS1200031C patent/HUS1200031I1/hu unknown
- 2012-12-14 HU HUS1200030C patent/HUS1200030I1/hu unknown
-
2013
- 2013-03-20 UY UY0001034691A patent/UY34691A/es unknown
- 2013-12-02 JP JP2013249334A patent/JP5953292B2/ja not_active Expired - Lifetime
-
2015
- 2015-04-28 JP JP2015092196A patent/JP5951843B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100754089B1 (ko) | 시클로프로필-접합 피롤리딘에 기초한 디펩티딜 펩티다제ⅳ의 억제제, 그의 제조방법 및 그의 용도 | |
AU2001245466A1 (en) | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl IV, processes for their preparation, and their use | |
US6573287B2 (en) | 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method | |
US6995180B2 (en) | Glycinenitrile-based inhibitors of dipeptidyl peptidase IV and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A107 | Divisional application of patent | ||
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
A101 | Application to extend term of patent right by permit | ||
FPAY | Annual fee payment |
Payment date: 20120802 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20130801 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20140808 Year of fee payment: 8 |
|
J204 | Request for invalidation trial [patent] | ||
J204 | Request for invalidation trial [patent] | ||
J121 | Written withdrawal of request for trial | ||
J204 | Request for invalidation trial [patent] | ||
J204 | Request for invalidation trial [patent] | ||
J204 | Request for invalidation trial [patent] | ||
J204 | Request for invalidation trial [patent] | ||
J121 | Written withdrawal of request for trial | ||
J501 | Disposition of invalidation of trial | ||
FPAY | Annual fee payment |
Payment date: 20150730 Year of fee payment: 9 |
|
J501 | Disposition of invalidation of trial | ||
J121 | Written withdrawal of request for trial | ||
J301 | Trial decision |
Free format text: TRIAL DECISION FOR INVALIDATION OF EXTENSION OF TERM REQUESTED 20150320 Effective date: 20160205 Free format text: TRIAL DECISION FOR INVALIDATION OF EXTENSION OF TERM REQUESTED 20150402 Effective date: 20160205 |
|
J2X1 | Appeal (before the patent court) |
Free format text: INVALIDATION OF EXTENSION OF TERM |
|
FPAY | Annual fee payment |
Payment date: 20160727 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20170804 Year of fee payment: 11 |
|
J122 | Written withdrawal of action (patent court) | ||
FPAY | Annual fee payment |
Payment date: 20180730 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20190729 Year of fee payment: 13 |